"Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients" - Christina Bennett
Targeted therapy showed a greater survival benefit than nontargeted therapy in a real world population of metastatic renal cell carcinoma patients, according to the results of a retrospective cohort study published in JAMA Network Open. “For many years we have adapted to targeted therapy instead of these cytokine-based therapies, and we know that in clinical trials, that the targeted therapies are better,” said Che-Kai Tsao, MD, associate professor, medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai who was not involved in the study. He added, “The reality is that, probably, the findings were long overdue and do not matter as much now because we are entering an age where patients are receiving combination targeted plus immunotherapy, or combination immunotherapies right up front.”
— Che-Kai Tsao, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Medical Director, Ruttenberg Treatment Center, The Tisch Cancer Institute, The Mount Sinai Hospital